Literature DB >> 27560455

Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis.

Jimmy Choi1, Cheryl M Corcoran2, Joanna M Fiszdon3, Michael Stevens1, Daniel C Javitt2, Melissa Deasy1, Lawrence C Haber1, Michael J Dewberry1, Godfrey D Pearlson1.   

Abstract

OBJECTIVE: Among individuals at clinical high risk (CHR) for psychosis, processing speed (PS) has been related to social and role functioning regardless of conversion to schizophrenia. This information processing dysfunction is a gateway to broader behavioral deficits such as difficulty executing social behaviors. We examined the feasibility of improving information processing relevant to social situations in CHR, including its sustainability at 2-month follow-up, and its association with concurrent social function.
METHOD: This was a double-blind RCT in which 62 CHR participants were randomized to Processing Speed Training (PST) or an active control matched for training format and the same dose and duration of treatment. PST is a tablet-based program that uses pupillometry-based neurofeedback to continually adjust training parameters for an optimal neurocognitive load and to improve visual scanning efficiency by inhibiting selection of nonessential targets and discriminating figure-ground details.
RESULTS: The PST group showed faster motoric and nonmotoric PS at post training and 2-month follow-up. At 2 month follow-up, the PST group reported better overall social adjustment. Changes in PS from baseline to 2 months were correlated with overall social adjustment and social avoidance in the entire sample. CONCLUSIONS AND IMPLICATIONS FOR PRACTICE: This is the first study to test focal neurofeedback-based cognitive training for PS deficits in the putatively prodromal phase of schizophrenia to address associated social morbidity. Targeting PS appears to be a promising pathway to decreasing comorbidity and mitigating a risk factor for psychosis. (PsycINFO Database Record (c) 2017 APA, all rights reserved).

Entities:  

Mesh:

Year:  2016        PMID: 27560455      PMCID: PMC5326611          DOI: 10.1037/prj0000217

Source DB:  PubMed          Journal:  Psychiatr Rehabil J        ISSN: 1095-158X


  57 in total

Review 1.  The prevention of schizophrenia.

Authors:  A R Yung; E Killackey; S E Hetrick; A G Parker; F Schultze-Lutter; J Klosterkoetter; R Purcell; P D Mcgorry
Journal:  Int Rev Psychiatry       Date:  2007-12

2.  Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial.

Authors:  Shaun M Eack; Deborah P Greenwald; Susan S Hogarty; Susan J Cooley; Ann Louise DiBarry; Debra M Montrose; Matcheri S Keshavan
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

3.  Neurocognitive performance of a community-based sample of young people at putative ultra high risk for psychosis: support for the processing speed hypothesis.

Authors:  Ian Kelleher; Aileen Murtagh; Mary C Clarke; Jennifer Murphy; Caroline Rawdon; Mary Cannon
Journal:  Cogn Neuropsychiatry       Date:  2012-09-20       Impact factor: 1.871

4.  A pilot study of cognitive training in clinical high risk for psychosis: initial evidence of cognitive benefit.

Authors:  Christine I Hooker; Emily E Carol; T J Eisenstein; Hong Yin; Sarah Hope Lincoln; Laura M Tully; David Dodell-Feder; Mor Nahum; Matcheri S Keshavan; Larry J Seidman
Journal:  Schizophr Res       Date:  2014-06-18       Impact factor: 4.939

5.  Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis.

Authors:  Ricardo E Carrión; Terry E Goldberg; Danielle McLaughlin; Andrea M Auther; Christoph U Correll; Barbara A Cornblatt
Journal:  Am J Psychiatry       Date:  2011-05-02       Impact factor: 18.112

6.  Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed.

Authors:  N Ojeda; J Peña; D J Schretlen; P Sánchez; E Aretouli; E Elizagárate; J Ezcurra; M Gutiérrez
Journal:  Schizophr Res       Date:  2012-01-05       Impact factor: 4.939

7.  Pilot study of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis.

Authors:  Danijela Piskulic; Mariapaola Barbato; Lu Liu; Jean Addington
Journal:  Psychiatry Res       Date:  2014-11-04       Impact factor: 3.222

8.  Prevalence and stability of social skill deficits in schizophrenia.

Authors:  K T Mueser; A S Bellack; M S Douglas; R L Morrison
Journal:  Schizophr Res       Date:  1991-09       Impact factor: 4.939

9.  Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis.

Authors:  Martijn Arns; Sabine de Ridder; Ute Strehl; Marinus Breteler; Anton Coenen
Journal:  Clin EEG Neurosci       Date:  2009-07       Impact factor: 1.843

10.  Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial.

Authors:  Til Wykes; Elizabeth Newton; Sabine Landau; Christopher Rice; Neil Thompson; Sophia Frangou
Journal:  Schizophr Res       Date:  2007-05-23       Impact factor: 4.939

View more
  17 in total

Review 1.  Attrition rates in trials for adolescents and young adults at clinical high-risk for psychosis: A systematic review and meta-analysis.

Authors:  Megan S Farris; Daniel J Devoe; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2019-08-18       Impact factor: 2.732

2.  Treatment of people at ultra-high risk for psychosis.

Authors:  Alison R Yung
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

3.  Attenuated psychotic symptom interventions in youth at risk of psychosis: A systematic review and meta-analysis.

Authors:  Daniel J Devoe; Megan S Farris; Parker Townes; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2018-05-11       Impact factor: 2.732

4.  Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis.

Authors:  Daniel J Devoe; Aaron Peterson; Jean Addington
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

5.  European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Andreas Erfurth; Stefano Barlati; Federico Zanca; Giulia Maria Giordano; Louise Birkedal Glenthøj; Merete Nordentoft; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

Review 6.  Annual Research Review: The contributions of the RDoC research framework on understanding the neurodevelopmental origins, progression and treatment of mental illnesses.

Authors:  Jennifer Pacheco; Marjorie A Garvey; Christopher S Sarampote; Elan D Cohen; Eric R Murphy; Stacia R Friedman-Hill
Journal:  J Child Psychol Psychiatry       Date:  2022-01-03       Impact factor: 8.265

7.  Decisional Informatics for Psychosocial Rehabilitation: A Feasibility Pilot on Tailored and Fluid Treatment Algorithms for Serious Mental Illness.

Authors:  Jimmy Choi; Paul H Lysaker; Morris D Bell; Lisa Dixon; Paul Margolies; Matthew Gold; Elizabeth Golden-Roose; Warren Thime; Lawrence C Haber; Michael J Dewberry; Michael Stevens; Godfrey D Pearlson; Joanna M Fiszdon
Journal:  J Nerv Ment Dis       Date:  2017-11       Impact factor: 2.254

8.  Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis.

Authors:  Jean Addington; Daniel J Devoe; Olga Santesteban-Echarri
Journal:  Curr Treat Options Psychiatry       Date:  2019-01-31

9.  Interventions for prodromal stage of psychosis.

Authors:  Dina Bosnjak Kuharic; Ivana Kekin; Joanne Hew; Martina Rojnic Kuzman; Livia Puljak
Journal:  Cochrane Database Syst Rev       Date:  2019-11-01

10.  The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review.

Authors:  Louise Birkedal Glenthøj; Carsten Hjorthøj; Tina Dam Kristensen; Charlie Andrew Davidson; Merete Nordentoft
Journal:  NPJ Schizophr       Date:  2017-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.